Ionis Pharmaceuticals’ Donidalorsen Shows Promise in Treating Rare Swelling Disease, Hereditary Angioedema

Ionis Pharmaceuticals reported that its drug, Donidalorsen, significantly reduced attacks in patients with hereditary angioedema, a severe swelling disease. The drug’s positive results in a late-stage study boosted Ionis’ shares. However, competition is noted from Takeda Pharmaceuticals and BioCryst Pharmaceuticals, which already have treatments in the market. Analysts await further data to assess Donidalorsen’s market potential. Ionis plans to submit a marketing application to the FDA, while Otsuka, holding rights in Europe, will apply to the European Medicines Agency. Other companies are also developing treatments for this condition.

To read more, click here.

[Source: Reuters, January 22nd, 2024]